The Mount Sinai Health System (New York, NY), Emergent BioSolutions (Gaithersburg, MD) and ImmunoTek Bio Centers (New Orleans, LA) will collaborate to develop, manufacture and conduct clinical trials to evaluate Emergent’s COVID-19 hyperimmune globulin product, COVID-HIG, including a post-exposure prophylaxis (PEP) study on healthcare providers at high risk of COVID-19 infection and other high-risk populations with $34.6 million in funding from the DOD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND). Read more.